Terifrac 3ml (Teriparatide Vials) 750mcg/3ml

Terifrac 3ml contains teriparatide, a parathyroid hormone analog used to support bone health. Store refrigerated between 2-8°C to maintain potency. Ideal for patients managing osteoporosis or bone density concerns. This 750mcg/3ml vial form is designed for subcutaneous use.

Strength

750mcg/3ml

Pack Size

Storage

2-8°

Manufacturer / TM Owner

Intas Pharmaceuticals Ltd

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Teriparc 3ml is used to treat osteoporosis in postmenopausal women and men at high risk of fracture. It may also support bone growth in patients with glucocorticoid-induced osteoporosis. This medication helps increase bone mineral density and reduce fracture risk over time. Patients often ask, 'what is teriparatide used for' when exploring bone health treatments.

Side Effects

Teriparatide works by stimulating new bone formation, which can improve bone strength and reduce fracture risk. Users may notice gradual improvements in mobility and comfort over time. The medication is administered as a daily injection under the skin. Effects vary by individual and treatment duration.

Precautions & Warnings

Store Terifrac 3ml vials refrigerated between 2-8°C and protect from light. Avoid freezing or shaking the vial. Discard any unused medication after the expiration date or if particles or discoloration appear. Keep out of reach of children and pets. Consult a healthcare provider before use if pregnant or breastfeeding.

Avoid Interactions

Teriparatide may interact with certain medications, including digoxin, as it can increase calcium levels. Avoid combining with other drugs that affect bone metabolism without medical supervision. Alcohol and tobacco may reduce the effectiveness of teriparatide. Always inform your healthcare provider about all medications and supplements you are taking.

References

Frequently Asked Questions

Each 3ml vial contains 28 doses. Once opened, it should be used within 28 days and stored refrigerated.

Yes, Terifrac 3ml is typically administered as a once-daily subcutaneous injection as prescribed by a healthcare provider.

Common side effects may include nausea, joint pain, or dizziness. Report persistent or severe effects to a healthcare provider.

Teriparc 3ml is not recommended for use during pregnancy unless specifically advised by a healthcare professional.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.